Since January first, Moderna (MRNA) has been in a powerful bullish trend, rocketing over eighty percent year-to-date and hitting fresh fifty-two-week highs around fifty-four dollars as of January twenty-second.
The stock started the year in the low thirties, consolidated early on, then exploded higher mid-month on breakthrough oncology data, breaking out of a multi-month falling wedge and cup-and-handle pattern with massive volume.
It’s now trading well above all key moving averages — the fifty-day around forty, one-hundred-day mid-thirties, and two-hundred-day low thirties — generating strong buy signals across the board.
MACD shows positive momentum at plus two point four six, ADX over fifty confirms a strong trend, and most oscillators like CCI and ROC are bullish.
That said, RSI at eighty-five is deeply overbought, along with STOCHRSI at one hundred and Williams %R near zero, flashing short-term exhaustion warnings after the vertical rally.
Support sits around forty-eight (near the pivot and recent MA20), with deeper fallback to forty or thirty-five if profit-taking hits.
Overall, the technical setup screams strong buy on the daily timeframe with clear upward momentum, but it’s stretched and due for a breather or pullback soon — classic high-volatility biotech move.